Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Payables: 2021-2025

Historic Payables for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $31.7 million.

  • Krystal Biotech's Payables fell 40.31% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.3 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of $59.0 million for FY2024, which is 174.23% up from last year.
  • Krystal Biotech's Payables amounted to $31.7 million in Q3 2025, which was up 19.56% from $26.5 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Payables peaked at $59.0 million during Q4 2024, and registered a low of $6.7 million during Q1 2021.
  • Over the past 3 years, Krystal Biotech's median Payables value was $29.4 million (recorded in 2023), while the average stood at $32.9 million.
  • As far as peak fluctuations go, Krystal Biotech's Payables surged by 663.94% in 2022, and later plummeted by 42.12% in 2023.
  • Quarterly analysis of 5 years shows Krystal Biotech's Payables stood at $16.3 million in 2021, then skyrocketed by 43.00% to $23.3 million in 2022, then declined by 7.70% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then crashed by 40.31% to $31.7 million in 2025.
  • Its Payables was $31.7 million in Q3 2025, compared to $26.5 million in Q2 2025 and $28.1 million in Q1 2025.